Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 19;15(12):1584.
doi: 10.3390/ph15121584.

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review

Affiliations
Review

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review

Martina Orlandi et al. Pharmaceuticals (Basel). .

Abstract

The role of Bronchoalveolar Lavage (BAL) in the evaluation of systemic sclerosis (SSc) interstitial lung disease (ILD) is still controversial. The aim of this systematic literature review was to investigate the use of BAL in SSc-ILD, and to focus on the pros and cons of its real-life application. Methods: PubMed, Cochrane, and Embase were questioned from inception until 31 December 2021. Results: Eighteen papers were finally analyzed. A positive correlation was observed between lung function and BAL cytology; in particular, BAL neutrophilia/granulocytosis was related to lower diffusing capacity for carbon monoxide (DLCO) values and lower forced vital capacity (FVC). Moreover, a positive correlation between BAL cellularity and high-resolution computed tomography (HRCT) findings has been reported by several authors. Cytokines, chemokines, growth factors, coagulation factors, and eicosanoids have all been shown to be present, more often and in higher quantities in SSc-ILD patients than in the health control and, in some cases, they were related to more severe pulmonary disease. There was no consensus regarding the role of BAL cellularity as a predictor of mortality.

Keywords: Bronchoalveolar Lavage; alveolitis; interstitial lung disease; scleroderma; systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

There are no conflict of interest in connection with the submitted manuscript; there was no financial support or other benefits from commercial sources for the work reported on in the manuscript. Please check the COI file attached.

Figures

Figure 1
Figure 1
PRISMA flow chart. Flow chart describing the study inclusion and exclusion process.

Similar articles

Cited by

References

    1. Orlandi M., Lepri G., Damiani A., Barsotti S., Di Battista M., Codullo V., Della Rossa A., Guiducci S., Allanore Y. One year in review 2020: Systemic sclerosis. Clin. Exp. Rheumatol. 2020;8((Suppl. 125)):3–17. - PubMed
    1. Volkmann E.R., Fischer A. Update on morbidity and mortality in systemic sclerosis–related interstitial lung disease. J. Scleroderma Relat. Disord. 2021;6:11–20. doi: 10.1177/2397198320915042. - DOI - PMC - PubMed
    1. Perelas A., Silver R.M., Arrossi A.V., Highland K.B. Systemic sclerosis-associated interstitial lung disease. Lancet Respir. Med. 2020;8:304–320. doi: 10.1016/S2213-2600(19)30480-1. - DOI - PubMed
    1. Desai S.R., Veeraraghavan S., Hansell D.M., Nikolakopolou A., Goh N.S., Nicholson A.G., Colby T.V., Denton C.P., Black C.M., du Bois R.M., et al. CT features of lung disease in patients with systemic sclerosis: Comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232:560–567. doi: 10.1148/radiol.2322031223. - DOI - PubMed
    1. Fujita J. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann. Rheum. Dis. 2001;60:281–283. doi: 10.1136/ard.60.3.281. - DOI - PMC - PubMed

LinkOut - more resources